Active Commitment to R&D
First written in FY2018-Q3. 21 of 29 entries say "Restated". Latest entry: FY2026.
56 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D expenses include ¥21.071 million in basic research costs incurred at the Cell Culture Center that cannot be allocated to individual segments, bringing total R&D expenses for the fiscal year to ¥359.025 million.」
R&D expenses increased from ¥290.242 million in the previous fiscal year to ¥359.025 million. The Company continued research into X-ray optical components, cell culture equipment, next-generation processing and polishing equipment, and regenerative medicine. - 2026-08-10AdvancedFinancial Results Presentation
「Focused on R&D, mainly related to new businesses, while capital investment to improve productivity also increased」
For the fiscal year ended June 2026, research and development expenses were ¥359 million and capital investment was ¥184 million, indicating the scale of investment in R&D and productivity improvements. - FY2026-H1RestatedAnnual report
「Group-wide R&D expenditures for the six-month consolidated accounting period amounted to ¥159.592 million. There were no material changes in the status of the Group's R&D activities during the six-month consolidated accounting period.」
R&D expenses amounted to ¥159.592 million, but it was stated that there were no material changes in the status of the R&D activities. - FY2025-H1RestatedAnnual report
「Group-wide R&D expenditures for the six-month consolidated accounting period amounted to ¥143.617 million.」
The Company recorded R&D expenses of ¥143.617 million and continued its R&D activities. - FY2025-H1RestatedAnnual report
「Group-wide R&D expenditures for the six-month consolidated accounting period amounted to ¥143.617 million. There were no material changes in the status of the Group's R&D activities during the six-month consolidated accounting period.」
The Company continued its R&D activities and recorded R&D expenses of ¥143.617 million for the six-month consolidated accounting period. It stated that there were no material changes in the status of its R&D activities. - FY2024AdvancedAnnual report
「In addition, the Company continued from the previous fiscal year to conduct R&D projects based on competitive funding, comprising commissioned research and research grants, with the aim of commercializing the results. R&D expenses include ¥19.364 million in basic research costs incurred at the Cell Culture Center that cannot be allocated to individual segments, bringing total R&D expenses for the fiscal year to ¥290.242 million.」
The Company continued R&D funded by competitive grants, with R&D expenses totaling ¥290.242 million, including ¥19.364 million in basic research costs at the Cell Culture Center. - FY2024-Q3RestatedAnnual report
「Group-wide R&D expenditures for the nine-month period ended 31 December amounted to ¥218.035 million. There were no material changes in the status of the Group's R&D activities during the nine-month period ended 31 December.」
The Company continued its R&D activities and recorded R&D expenses of ¥218.035 million for the nine-month consolidated period ended 31 December. It stated that there were no material changes in the status of its R&D activities. - FY2024-Q2RestatedAnnual report
「Group-wide R&D expenditures for the six-month period ended 30 September amounted to ¥149.816 million. There were no material changes in the status of the Group's R&D activities during the six-month period ended 30 September.」
The Company continued its R&D activities and recorded R&D expenses of ¥149.816 million for the six-month consolidated period ended 30 September. It stated that there were no material changes in the status of its R&D activities. - FY2024-Q1RestatedAnnual report
「Group-wide R&D expenditures for the three-month period ended 30 June amounted to ¥74.561 million. There were no material changes in the status of the Group's R&D activities during the three-month period ended 30 June.」
The Company continued its R&D activities and recorded R&D expenses of ¥74.561 million for the three-month consolidated period ended 30 June. It stated that there were no material changes in the status of its R&D activities. - FY2023-Q3RestatedAnnual report
「Group-wide R&D expenditures for the nine-month period ended 31 December amounted to ¥216.112 million. There were no material changes in the status of the Group's R&D activities during the nine-month period ended 31 December.」
The Company continued its R&D activities and recorded cumulative R&D expenses of ¥216.112 million. It stated that there were no material changes in the status of its R&D activities. - FY2023-Q2RestatedAnnual report
「Group-wide R&D expenditures for the six-month period ended 30 September amounted to ¥150.156 million. There were no material changes in the status of the Group's R&D activities during the six-month period ended 30 September.」
The Company continued its R&D activities and recorded R&D expenses of ¥150.156 million for the six-month consolidated period ended 30 September. It stated that there were no material changes in the status of its R&D activities. - FY2023-Q1RestatedAnnual report
「Group-wide R&D expenditures for the three-month period ended 30 June amounted to ¥82.816 million. There were no material changes in the status of the Group's R&D activities during the three-month period ended 30 June.」
The Company continued its R&D activities and recorded R&D expenses of ¥82.816 million for the three-month consolidated period ended 30 June. It stated that there were no material changes in the status of its R&D activities. - FY2022AdvancedAnnual report
「In addition, the Company is currently conducting R&D projects based on 4 competitive funding programs, comprising commissioned research and research grants, with the aim of commercializing the results. R&D expenses include ¥11.065 million in basic research costs incurred at the Cell Culture Center that cannot be allocated to individual segments, bringing total R&D expenses for the fiscal year to ¥263.396 million.」
The Company continued R&D under 4 competitive funding programs and recorded annual R&D expenses of ¥263.396 million, including ¥11.065 million in basic research costs at the Cell Culture Center. - FY2022-Q3RestatedAnnual report
「The Group's R&D expenditures for the nine-month period ended 31 December amounted to ¥202.755 million. There were no material changes in the status of the Group's R&D activities during the nine-month period ended 31 December.」
The Company continued its R&D activities and reported R&D expenses of ¥202.755 million for the nine-month consolidated period ended 31 December. There were no material changes in the status of its R&D activities. - FY2022-Q2RestatedAnnual report
「The Group's R&D expenditures for the six-month period ended 30 September amounted to ¥133.674 million. There were no material changes in the status of the Group's R&D activities during the six-month period ended 30 September.」
The Company continued its R&D activities and reported R&D expenses of ¥133.674 million for the six-month consolidated period ended 30 September. There were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「Group-wide R&D expenditures for the three-month period ended 30 June amounted to ¥79.192 million. There were no material changes in the status of the Group's R&D activities during the three-month period ended 30 June.」
The Company continued its R&D activities and reported R&D expenses of ¥79.192 million for the three-month period ended 30 June. There were no material changes in the status of its R&D activities. - FY2021-Q3RestatedAnnual report
「R&D expenditures for the nine-month period ended 31 December amounted to ¥184.835 million. There were no material changes in the status of the Company's R&D activities during the nine-month period ended 31 December.」
The Company continued its R&D activities and reported R&D expenses of ¥184.835 million for the nine-month period. There were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「R&D expenditures for the six-month period ended 30 September amounted to ¥122.745 million. There were no material changes in the status of the Company's R&D activities during the six-month period ended 30 September.」
The Company continued its R&D activities and recorded cumulative R&D expenses of ¥122.745 million. It stated that there were no material changes in the status of its R&D activities. - FY2021-Q1RestatedAnnual report
「Research and development activities during the three-month period ended the first quarter amounted to ¥72.511 million. There were no material changes in the status of the Company's research and development activities during the period.」
The Company continued its research and development activities and reported research and development expenses of ¥72.511 million for the three-month period ended the first quarter. There were no material changes in the status of these activities. - FY2020AdvancedAnnual report
「Total research and development expenses for the fiscal year amounted to ¥207.955 million.」
Research and development expenses increased from ¥183.433 million in the previous period to ¥207.955 million. The Company continues research and development into next-generation mirrors, nanofabrication and measurement technologies, cell culture equipment and regenerative medicine. - FY2020-Q3RestatedAnnual report
「Research and development activities during the nine-month period ended the third quarter amounted to ¥181.403 million. There were no material changes in the status of the Company's research and development activities during the period.」
Research and development expenses for the nine-month period ended the third quarter amounted to ¥181.403 million. The Company stated that there were no material changes in the status of its research and development activities. - FY2020-Q2RestatedAnnual report
「Research and development activities during the six-month period ended the second quarter amounted to ¥130.313 million. There were no material changes in the status of the Company's research and development activities during the period.」
The Company continued its research and development activities, with cumulative research and development expenses reaching ¥130.313 million. There were no material changes in the status of these activities. - FY2020-Q1RestatedAnnual report
「Research and development activities during the three-month period ended the first quarter amounted to ¥63.665 million. There were no material changes in the status of the Company's research and development activities during the period.」
The Company continued its research and development activities and reported research and development expenses of ¥63.665 million for the three-month period ended the first quarter. There were no material changes in the status of these activities. - FY2019AdvancedAnnual report
「The Company's research and development expenses for the fiscal year amounted to ¥183.433 million.」
Research and development expenses increased from ¥173.902 million in the previous period to ¥183.433 million. The Company is also advancing development of CARE for practical application, new measurement equipment, next-generation mirrors and cell culture equipment. - FY2019-Q3RestatedAnnual report
「Research and development activities during the nine-month period ended the third quarter amounted to ¥170.962 million. There were no material changes in the status of the Company's research and development activities during the period.」
The Company continued its research and development activities and reported research and development expenses of ¥170.962 million for the nine-month period ended the third quarter. There were no material changes in the status of these activities. - FY2019-Q2RestatedAnnual report
「Research and development activities during the six-month period ended the second quarter amounted to ¥110.015 million. There were no material changes in the status of the Company's research and development activities during the period.」
The Company continued its research and development activities and reported expenses of ¥110.015 million for the six-month period ended the second quarter. There were no material changes in the status of these activities. - FY2019-Q1RestatedAnnual report
「Research and development activities during the three-month period ended the first quarter amounted to ¥52.926 million. There were no material changes in the status of the Company's research and development activities during the period.」
The Company continued its research and development activities and reported research and development expenses of ¥52.926 million for the nine-month period. - FY2018AdvancedAnnual report
「The Company's research and development expenses for the fiscal year amounted to ¥173.902 million.」
The Company continues multiple projects, including Optical, large-scale iPS cell culture and elastic cartilage devices for regenerative medicine, and reports annual research and development expenses of ¥173.902 million. - FY2018-Q3First statedAnnual report
「The Company also pursued research and development actively.」
Research and development activities during the nine-month period amounted to ¥140.242 million.